InflaRx NVIFRX +2.13%31 ROC (Joel Greenblatt) % is -1,995.82% as of Mar. 2026. GuruFocus rates IFRX with a GF Score™ of 31/100. The stock has 5 warning signs investors should review. Among 1,319 Biotechnology companies, InflaRx NV ranks worse than 78.39% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. InflaRx NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1,995.82%.
The historical rank and industry rank for InflaRx NV's ROC (Joel Greenblatt) % or its related term are showing as below:
IFRX'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -13418.08 Med: -3194.49 Max: -1189.59
Current: -2716.19
During the past 11 years, InflaRx NV's highest ROC (Joel Greenblatt) % was -1189.59%. The lowest was -13418.08%. And the median was -3194.49%.
IFRX's ROC (Joel Greenblatt) % is ranked worse than 78.39% of 1319
companies
in the Biotechnology industry
Industry Median: -291.86
vs IFRX: -2716.19
InflaRx NV's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 11.60% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
InflaRx NV ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for InflaRx NV's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IFRX vs BCYC, ELDN, ZNTL: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, InflaRx NV's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InflaRx NV ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InflaRx NV's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where InflaRx NV's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -1,995.82% mean?
InflaRx NV (IFRX) has a ROC (Joel Greenblatt) % of -1,995.82% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on InflaRx NV and its competitors. According to the industry distribution chart, InflaRx NV ranks #1034 out of 1319 companies in the Biotechnology industry, placing it in the top 78.4%.
Is InflaRx NV's ROC (Joel Greenblatt) % too high?
InflaRx NV's current ROC (Joel Greenblatt) % is -1,995.82%. Based on the distribution chart, InflaRx NV ranks #1034 out of 1319 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, InflaRx NV has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does InflaRx NV's ROC (Joel Greenblatt) % compare to BCYC and ELDN?
According to the Biotechnology industry distribution chart, InflaRx NV ranks #1034 out of 1319 companies for ROC (Joel Greenblatt) %. This places InflaRx NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on InflaRx NV and its competitors. InflaRx NV's current ROC (Joel Greenblatt) % is -1,995.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InflaRx NV stock overvalued right now?
InflaRx NV (IFRX) has a current ROC (Joel Greenblatt) % of -1,995.82%. The current ROC (Joel Greenblatt) % is -1,995.82%. InflaRx NV's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For InflaRx NV (IFRX), the current ROC (Joel Greenblatt) % is -1,995.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
31GF Score
Get the complete analysis for IFRX
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IFRX has been successfully added to your 
